Prospective Trial of Monocyte Count as a Biomarker of Hand-Foot Syndrome Among Patients With Soft Tissue Sarcomas Treated With Pegylated Liposomal Doxorubicin and Ifosfamide

Pegylated liposomal doxorubicin (PLD) is widely used and can be used for prolonged periods, with the limiting toxicity usually being hand-foot syndrome (HFS). The pharmacokinetics of PLD is variable between patients, leading to variability in the risk of developing HFS. Dosing based on body surface...

Descripción completa

Detalles Bibliográficos
Autores principales: Skubitz, Keith M, Lindgren, Bruce R, Domingo-Musibay, Evidio, Cheng, Edward Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135613/
https://www.ncbi.nlm.nih.gov/pubmed/35651410
http://dx.doi.org/10.7759/cureus.24498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135613/
https://www.ncbi.nlm.nih.gov/pubmed/35651410
http://dx.doi.org/10.7759/cureus.24498

Ejemplares similares